Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Nutr Biochem. 2021 Aug 15;99:108842. doi: 10.1016/j.jnutbio.2021.108842

Figure 3. Effect of MAPK inhibitors on Smad2 phosphorylation (linker or C-terminus), TGFβR2, and PTHrP secretion in MDA-SA cells treated with curcumin and/or TGFβ.

Figure 3.

A) Effect of curcumin (30 uM, 16h pre-treatment) and/or TGFβ (1h) on both Smad2 linker-region phosphorylation (pSmad2-L) and receptor-mediated C-terminal phosphorylation (pSmad2) (densitometric quantitation [n=3] of pSmad2-L, right panel). B) Effect of MAPK inhibitors (3 h pre-treatment prior to curcumin) of p38 (SB202190, 10 μM) or JNK (SP600125, 25 μM) on Smad2 linker or C-terminal phosphorylation or TGFβR2 protein in curcumin and/or TGFβ-treated cells (16h curcumin followed by 1h TGFβ). Representative of two experiments. C) Effect of JNK or p38 inhibitor (1h pre-treatment, 25 μM SP600125 or 10 μM SB202190, respectively) on PTHrP secretion in cells treated with curcumin and/or TGFβ (30 μM curcumin, 4 hr prior to addition TGFβ; n=3–8/group). Because inhibitors decreased constitutive PTHrP levels, data are expressed as % change relative to constitutive (control) levels. ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs control or as specified.